JP2020500010A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500010A5 JP2020500010A5 JP2019520983A JP2019520983A JP2020500010A5 JP 2020500010 A5 JP2020500010 A5 JP 2020500010A5 JP 2019520983 A JP2019520983 A JP 2019520983A JP 2019520983 A JP2019520983 A JP 2019520983A JP 2020500010 A5 JP2020500010 A5 JP 2020500010A5
- Authority
- JP
- Japan
- Prior art keywords
- modified
- family
- affinity
- domain
- igsf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002865 immune cell Anatomy 0.000 claims description 68
- 108090000623 proteins and genes Proteins 0.000 claims description 50
- 230000027455 binding Effects 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 36
- 239000012678 infectious agent Substances 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 34
- 102000005962 receptors Human genes 0.000 claims description 32
- 108020003175 receptors Proteins 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 230000002519 immonomodulatory effect Effects 0.000 claims description 26
- 230000028993 immune response Effects 0.000 claims description 21
- 108060003951 Immunoglobulin Proteins 0.000 claims description 20
- 102000018358 immunoglobulin Human genes 0.000 claims description 20
- 208000015181 infectious disease Diseases 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 230000002458 infectious effect Effects 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 17
- -1 CD86 Proteins 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 238000006467 substitution reaction Methods 0.000 claims description 16
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 230000004936 stimulating effect Effects 0.000 claims description 12
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 10
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 10
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 10
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 10
- 102100035488 Nectin-2 Human genes 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 10
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 10
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 10
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 10
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 10
- 108091008042 inhibitory receptors Proteins 0.000 claims description 10
- 230000011664 signaling Effects 0.000 claims description 9
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 8
- 102100038077 CD226 antigen Human genes 0.000 claims description 8
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 8
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 8
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 8
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims description 8
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 8
- 102000017578 LAG3 Human genes 0.000 claims description 8
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 8
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 6
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 6
- 101001002552 Homo sapiens Immunoglobulin superfamily member 11 Proteins 0.000 claims description 6
- 101000743493 Homo sapiens V-set and immunoglobulin domain-containing protein 8 Proteins 0.000 claims description 6
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 6
- 102100021032 Immunoglobulin superfamily member 11 Human genes 0.000 claims description 6
- 102000002698 KIR Receptors Human genes 0.000 claims description 6
- 102100029740 Poliovirus receptor Human genes 0.000 claims description 6
- 102100038355 V-set and immunoglobulin domain-containing protein 8 Human genes 0.000 claims description 6
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 6
- 230000033228 biological regulation Effects 0.000 claims description 6
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 102100024263 CD160 antigen Human genes 0.000 claims description 4
- 102100038078 CD276 antigen Human genes 0.000 claims description 4
- 101710185679 CD276 antigen Proteins 0.000 claims description 4
- 108010062802 CD66 antigens Proteins 0.000 claims description 4
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims description 4
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims description 4
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 4
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 claims description 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 4
- 102100031351 Galectin-9 Human genes 0.000 claims description 4
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims description 4
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 4
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 claims description 4
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 4
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 claims description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 4
- 102100034980 ICOS ligand Human genes 0.000 claims description 4
- 101710093458 ICOS ligand Proteins 0.000 claims description 4
- 108090001090 Lectins Proteins 0.000 claims description 4
- 102000004856 Lectins Human genes 0.000 claims description 4
- 108091054438 MHC class II family Proteins 0.000 claims description 4
- 102000043131 MHC class II family Human genes 0.000 claims description 4
- 101150065403 NECTIN2 gene Proteins 0.000 claims description 4
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims description 4
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims description 4
- 102000002356 Nectin Human genes 0.000 claims description 4
- 108060005251 Nectin Proteins 0.000 claims description 4
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 claims description 4
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 claims description 4
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 claims description 4
- 108091008874 T cell receptors Proteins 0.000 claims description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 4
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 4
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 4
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 4
- 210000002798 bone marrow cell Anatomy 0.000 claims description 4
- 230000005779 cell damage Effects 0.000 claims description 4
- 208000037887 cell injury Diseases 0.000 claims description 4
- 230000001605 fetal effect Effects 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 239000002523 lectin Substances 0.000 claims description 4
- 210000000265 leukocyte Anatomy 0.000 claims description 4
- 210000002751 lymph Anatomy 0.000 claims description 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 4
- 241001529453 unidentified herpesvirus Species 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 231100000433 cytotoxic Toxicity 0.000 claims description 3
- 230000001472 cytotoxic effect Effects 0.000 claims description 3
- 230000000593 degrading effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 230000008672 reprogramming Effects 0.000 claims description 3
- 210000001082 somatic cell Anatomy 0.000 claims description 3
- 230000017423 tissue regeneration Effects 0.000 claims description 3
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 241000709687 Coxsackievirus Species 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101001102797 Homo sapiens Transmembrane protein PVRIG Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 102000003945 NF-kappa B Human genes 0.000 claims description 2
- 108010057466 NF-kappa B Proteins 0.000 claims description 2
- 241000125945 Protoparvovirus Species 0.000 claims description 2
- 241000710960 Sindbis virus Species 0.000 claims description 2
- 230000006044 T cell activation Effects 0.000 claims description 2
- 102100039630 Transmembrane protein PVRIG Human genes 0.000 claims description 2
- 241000700618 Vaccinia virus Species 0.000 claims description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 2
- 239000002257 antimetastatic agent Substances 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 244000309459 oncolytic virus Species 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 208000003265 stomatitis Diseases 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims 4
- 238000012986 modification Methods 0.000 claims 4
- 230000012121 regulation of immune response Effects 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 108010043610 KIR Receptors Proteins 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410827P | 2016-10-20 | 2016-10-20 | |
| US62/410,827 | 2016-10-20 | ||
| US201762475210P | 2017-03-22 | 2017-03-22 | |
| US62/475,210 | 2017-03-22 | ||
| US201762537921P | 2017-07-27 | 2017-07-27 | |
| US62/537,921 | 2017-07-27 | ||
| PCT/US2017/057743 WO2018075978A1 (en) | 2016-10-20 | 2017-10-20 | Secretable variant immunomodulatory proteins and engineered cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020500010A JP2020500010A (ja) | 2020-01-09 |
| JP2020500010A5 true JP2020500010A5 (enExample) | 2020-11-26 |
Family
ID=60480369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520983A Pending JP2020500010A (ja) | 2016-10-20 | 2017-10-20 | 分泌性バリアント免疫調節タンパク質および改変細胞療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200040059A1 (enExample) |
| EP (2) | EP3872180A1 (enExample) |
| JP (1) | JP2020500010A (enExample) |
| KR (1) | KR20190099194A (enExample) |
| CN (1) | CN110352245A (enExample) |
| AU (1) | AU2017345764A1 (enExample) |
| CA (1) | CA3040296A1 (enExample) |
| IL (1) | IL266045A (enExample) |
| SG (1) | SG11201903407XA (enExample) |
| WO (1) | WO2018075978A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201802728T4 (tr) | 2013-10-25 | 2018-03-21 | Psioxus Therapeutics Ltd | Heterolog genlerle donatılmış onkolitik adenovirüsler. |
| GB201414021D0 (en) | 2014-08-07 | 2014-09-24 | Nascient Ltd | Biological materials and uses thereof |
| EP3283508B1 (en) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| BR122018004815A2 (pt) | 2015-04-30 | 2019-09-10 | Psioxus Therapeutics Ltd | adenovírus oncolítico que codifica proteína b7 |
| MA43163A (fr) | 2015-11-02 | 2018-09-12 | Five Prime Therapeutics Inc | Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer |
| EA201891022A1 (ru) | 2015-12-17 | 2019-01-31 | Псайоксус Терапьютикс Лимитед | Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| WO2021042072A1 (en) * | 2019-09-01 | 2021-03-04 | Exuma Biotech Corp. | Methods and compositions for the modification and delivery of lymphocytes |
| KR102824067B1 (ko) | 2016-04-15 | 2025-06-23 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
| EP3443000B1 (en) | 2016-04-15 | 2025-11-12 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| CN119614520A (zh) | 2016-08-29 | 2025-03-14 | 阿卡米斯生物公司 | 携带双特异性t细胞衔接器的腺病毒 |
| CA3054068A1 (en) * | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| CN110809581A (zh) | 2017-03-16 | 2020-02-18 | 高山免疫科学股份有限公司 | Pd-l2变体免疫调节蛋白及其用途 |
| JP2020517913A (ja) | 2017-04-28 | 2020-06-18 | ファイブ プライム セラピューティクス， インコーポレイテッド | Ｃｄ８０細胞外ドメインポリペプチドによる治療方法 |
| WO2018220207A1 (en) | 2017-06-01 | 2018-12-06 | Psioxus Therapeutics Limited | Oncolytic virus and method |
| UA128472C2 (uk) | 2017-08-25 | 2024-07-24 | Файв Прайм Терапеутікс Інк. | B7-h4 антитіла і методи їх використання |
| KR102813968B1 (ko) | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| MX2020004540A (es) | 2017-10-18 | 2020-08-03 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras de ligando icos variante y composiciones y metodos relacionados. |
| EP3735417A1 (en) | 2018-01-03 | 2020-11-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| GB201801614D0 (en) | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
| BR112020016986A2 (pt) | 2018-02-21 | 2021-03-02 | Five Prime Therapeutics, Inc. | formulações de anticorpo contra b7-h4 |
| CA3091801A1 (en) | 2018-03-02 | 2019-09-06 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| KR20210049814A (ko) * | 2018-08-29 | 2021-05-06 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 fc 융합 단백질 투약 요법 |
| WO2020052645A1 (zh) * | 2018-09-14 | 2020-03-19 | 上海原能细胞医学技术有限公司 | 表面包含免疫调节剂的细胞及其用途 |
| CN113544144A (zh) * | 2018-09-19 | 2021-10-22 | 高山免疫科学股份有限公司 | 变体cd80融合蛋白和相关构建体的方法和用途 |
| US20220144913A1 (en) * | 2019-02-27 | 2022-05-12 | The General Hospital Corporation | Personalized and timed release of biomolecules |
| CN113087806B (zh) * | 2019-12-31 | 2022-09-06 | 华东师范大学 | 靶向多种肿瘤的新型car-t细胞及其制备和方法 |
| WO2021197430A1 (en) * | 2020-04-01 | 2021-10-07 | Nanjing Legend Biotech Co., Ltd. | Compositions and methods for reducing graft rejection in allogeneic cell therapy |
| CN115812077A (zh) | 2020-05-08 | 2023-03-17 | 高山免疫科学股份有限公司 | April和baff抑制性免疫调节蛋白及其使用方法 |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| JP7758739B2 (ja) * | 2020-12-23 | 2025-10-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アンカー改変型抗体をコードする核酸およびその使用 |
| CN113308491B (zh) * | 2021-05-25 | 2022-03-22 | 北京鼎成肽源生物技术有限公司 | 一种共表达nfat和人dnam-1蛋白的重组质粒、重组细胞及其构建方法和应用 |
| AU2022316889A1 (en) * | 2021-07-26 | 2024-01-25 | Kite Pharma, Inc. | Dnvsig3 and dnvsig8 receptors and methods of using the same |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| US20020159979A1 (en) | 1994-06-06 | 2002-10-31 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| FR2735789B1 (fr) | 1995-06-23 | 1997-07-25 | Centre Nat Rech Scient | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant |
| US6632670B1 (en) | 1995-09-08 | 2003-10-14 | Genzyme Corporation | AAV vectors for gene therapy |
| US7001765B2 (en) | 1996-03-06 | 2006-02-21 | Medigene Ag | Adeno-associated virus vector for boosting immunogenicity of cells |
| AU8828598A (en) | 1997-08-15 | 1999-03-08 | Rubicon Laboratory, Inc. | Retrovirus and viral vectors |
| JP2001517454A (ja) | 1997-09-19 | 2001-10-09 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株 |
| GB9801930D0 (en) | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
| US20040063094A1 (en) | 1998-05-20 | 2004-04-01 | Biovex Limited | Mutant herpes simplex viruses and uses thereof |
| US6436392B1 (en) | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
| AU780231B2 (en) | 1998-11-10 | 2005-03-10 | University Of North Carolina At Chapel Hill, The | Virus vectors and methods of making and administering the same |
| GB9904582D0 (en) | 1999-02-26 | 1999-04-21 | Nycomed Imaging As | Process |
| US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| DE19933288A1 (de) | 1999-07-15 | 2001-01-18 | Medigene Ag | Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung |
| US7241447B1 (en) | 1999-10-07 | 2007-07-10 | University Of Iowa Research Foundation | Adeno-associated virus vectors and uses thereof |
| US7329728B1 (en) | 1999-10-25 | 2008-02-12 | The Scripps Research Institute | Ligand activated transcriptional regulator proteins |
| WO2001045737A2 (en) | 1999-12-22 | 2001-06-28 | Onyx Pharmaceuticals, Inc. | Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth |
| KR100802403B1 (ko) | 2000-01-21 | 2008-02-13 | 바이오벡스 리미티드 | 바이러스 주 |
| US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| US7011972B2 (en) | 2000-07-18 | 2006-03-14 | The Scripps Research Institute | Fusion polypeptide comprising two ligand binding domains |
| US6653103B2 (en) | 2001-03-30 | 2003-11-25 | Wisconsin Alumni Research Foundation | Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides |
| DE60239394D1 (de) | 2001-05-11 | 2011-04-21 | Wellstat Biologics Corp | Onkolytische virustherapie |
| CA2452517A1 (en) | 2001-07-11 | 2003-01-23 | University Of Miami | Recombinant vsv for the treatment of tumor cells |
| CN1304559C (zh) | 2001-10-09 | 2007-03-14 | 杭州康科生物技术有限公司 | 表达热休克蛋白的溶瘤微生物及其应用 |
| AU2003258060B2 (en) | 2002-03-27 | 2007-07-12 | Baylor College Of Medicine | Potent oncolytic herpes simplex virus for cancer therapy |
| US20030225260A1 (en) | 2002-04-30 | 2003-12-04 | Snyder Richard O. | Production of recombinant AAV virions |
| RU2314830C2 (ru) | 2002-06-21 | 2008-01-20 | Веллстат Байолоджикс Корпорейшн | Введение терапевтических вирусов |
| CN1820078A (zh) | 2002-09-09 | 2006-08-16 | 田纳西大学研究基金会 | 弹状病毒的重组突变体及其应用方法 |
| US7731974B2 (en) | 2003-03-27 | 2010-06-08 | Ottawa Hospital Research Institute | Mutant vesicular stomatitis viruses and uses thereof |
| EP1606411B1 (en) | 2003-03-27 | 2008-12-10 | Ottawa Health Research Institute | Mutant vesicular stomatitis viruses and use thereof |
| SG179291A1 (en) | 2003-06-18 | 2012-04-27 | Genelux Corp | Modified recombinant vaccinia viruses and other microorganisms, uses thereof |
| EP2298926A1 (en) | 2003-09-30 | 2011-03-23 | The Trustees of The University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
| JP2007511216A (ja) | 2003-11-17 | 2007-05-10 | クルセイド ラボラトリーズ リミテッド | 変異ウイルス |
| GB0326798D0 (en) | 2003-11-17 | 2003-12-24 | Crusade Lab Ltd | Methods for generating mutant virus |
| US7897146B2 (en) | 2003-11-17 | 2011-03-01 | Crusade Laboratories Limited | Treatment using herpes simplex virus |
| WO2005116224A2 (en) | 2004-05-18 | 2005-12-08 | Children's Memorial Hospital | Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system |
| US7427396B2 (en) | 2004-06-03 | 2008-09-23 | Genzyme Corporation | AAV vectors for gene delivery to the lung |
| WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| EP1819823A2 (en) | 2004-12-01 | 2007-08-22 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
| AU2006252406B2 (en) | 2005-06-01 | 2012-05-17 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| US8986672B2 (en) | 2005-06-23 | 2015-03-24 | The University Of Houston | Use of mutant Herpes Simplex Virus-2 for cancer therapy |
| US7943374B2 (en) | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
| GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
| SG173337A1 (en) | 2006-07-21 | 2011-08-29 | California Inst Of Techn | Targeted gene delivery for dendritic cell vaccination |
| EP2426142A3 (en) | 2006-10-16 | 2012-06-13 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
| WO2008140621A2 (en) | 2006-12-21 | 2008-11-20 | Mount Sinai School Of Medicine Of New York University | Transgenic oncolytic viruses and uses thereof |
| GB2446721B (en) | 2007-02-16 | 2009-03-25 | Crusade Lab Ltd | Herpes simplex viruses and methods of viral replication |
| JP5213075B2 (ja) | 2007-06-15 | 2013-06-19 | ジェネラックス・コーポレイション | 腫瘍の画像化および／または処置のための微生物 |
| EP2514762B1 (en) * | 2007-07-13 | 2015-04-08 | The Johns Hopkins University | B7-DC variants |
| CA2693623A1 (en) | 2007-07-18 | 2009-01-22 | Genelux Corporation | Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy |
| WO2009054996A2 (en) | 2007-10-25 | 2009-04-30 | Genelux Corporation | Systems and methods for viral therapy |
| US8313896B2 (en) | 2008-04-04 | 2012-11-20 | The General Hospital Corporation | Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer |
| EP2300023A2 (en) | 2008-05-16 | 2011-03-30 | Genelux Corporation | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
| WO2009148488A2 (en) | 2008-05-29 | 2009-12-10 | The General Hospital Corporation | Use of oncolytic herpes viruses for killing cancer stem cells |
| WO2010059253A2 (en) | 2008-11-24 | 2010-05-27 | Massachusets Institute Of Technology | Methods and compositions for localized agent delivery |
| US8481297B2 (en) | 2009-01-08 | 2013-07-09 | Yale University | Compositions and methods of use of an oncolytic vesicular stomatitis virus |
| EP2283810A1 (en) | 2009-07-16 | 2011-02-16 | University College Cork-National University of Ireland, Cork | Orally administered bacteria as vehicles for systemic delivery of agents |
| US20150359909A1 (en) | 2009-07-16 | 2015-12-17 | University College Cork-National University Of Ireland, Cork | Orally administered bacteria as vehicles for systemic delivery of agents |
| WO2011011584A1 (en) | 2009-07-24 | 2011-01-27 | Immune Design Corp | Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| AU2012207356A1 (en) | 2011-01-18 | 2013-08-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| US9409987B2 (en) * | 2011-04-15 | 2016-08-09 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
| WO2012149364A1 (en) | 2011-04-28 | 2012-11-01 | Diamond Don J | Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy |
| SG11201400527XA (en) | 2011-09-16 | 2014-04-28 | Univ Pennsylvania | Rna engineered t cells for the treatment of cancer |
| CN107496932A (zh) | 2012-02-27 | 2017-12-22 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
| EP2831095B1 (en) | 2012-03-30 | 2018-11-28 | Immune Design Corp. | Lentiviral vector particles having improved transduction efficiency for cells expressing dc-sign |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| US9327014B2 (en) * | 2012-12-04 | 2016-05-03 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| WO2014198002A1 (en) | 2013-06-14 | 2014-12-18 | Ottawa Hospital Research Institute | A bacterium producing an interferon binding protein and uses thereof |
| US10238700B2 (en) | 2014-01-02 | 2019-03-26 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| ES2792849T3 (es) * | 2014-02-10 | 2020-11-12 | Univ Emory | Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer |
| SG10201901735XA (en) * | 2014-09-03 | 2019-03-28 | Bavarian Nordic As | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
| EP3020816A1 (en) | 2014-11-11 | 2016-05-18 | University College Cork | Bacterial mediated gene therapy |
| CN107708725A (zh) * | 2015-04-02 | 2018-02-16 | 坎库雷有限公司 | 用于引发免疫应答的剂和组合物 |
| EP3283508B1 (en) * | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| EA201890729A1 (ru) * | 2015-09-14 | 2018-09-28 | Элпайн Имьюн Сайнс, Инк. | Настраиваемые варианты доменов суперсемейства иммуноглобулинов и терапия сконструированными клетками |
| KR102824067B1 (ko) * | 2016-04-15 | 2025-06-23 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
| EP3443000B1 (en) * | 2016-04-15 | 2025-11-12 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| CA3022331A1 (en) * | 2016-05-18 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof |
-
2017
- 2017-10-20 AU AU2017345764A patent/AU2017345764A1/en not_active Abandoned
- 2017-10-20 US US16/343,709 patent/US20200040059A1/en not_active Abandoned
- 2017-10-20 CN CN201780078110.1A patent/CN110352245A/zh active Pending
- 2017-10-20 CA CA3040296A patent/CA3040296A1/en not_active Abandoned
- 2017-10-20 EP EP21154405.1A patent/EP3872180A1/en not_active Withdrawn
- 2017-10-20 SG SG11201903407XA patent/SG11201903407XA/en unknown
- 2017-10-20 WO PCT/US2017/057743 patent/WO2018075978A1/en not_active Ceased
- 2017-10-20 KR KR1020197013562A patent/KR20190099194A/ko not_active Ceased
- 2017-10-20 JP JP2019520983A patent/JP2020500010A/ja active Pending
- 2017-10-20 EP EP17804986.2A patent/EP3529361B1/en active Active
-
2019
- 2019-04-15 IL IL266045A patent/IL266045A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500010A5 (enExample) | ||
| Perez-Gracia et al. | Orchestrating immune check-point blockade for cancer immunotherapy in combinations | |
| EP3636761B1 (en) | Antigen-binding protein recognizing mage-a4-derived peptide | |
| JP2018534245A5 (enExample) | ||
| JP6666267B2 (ja) | Ｏｘ４０ｌ融合タンパク質およびその使用 | |
| Singh et al. | 4-1BB immunotherapy: advances and hurdles | |
| EP3876950A1 (en) | Anti-gpc3 chimeric antigen receptors (cars) in combination with trans co-stimulatory molecules and therapeutic uses thereof | |
| JP7433348B2 (ja) | キメラポリペプチド及びそれらの細胞膜における局在を変更する方法 | |
| AU2019299439A1 (en) | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof | |
| EP3766895A1 (en) | Methods and compositions for adoptive cell therapy | |
| JP2018532432A (ja) | Ｔｒａｆ誘導ドメインを含有するキメラ受容体ならびに関連する組成物および方法 | |
| CN110177803A (zh) | 用于使用融合蛋白进行tcr重新编程的组合物和方法 | |
| WO2018023093A1 (en) | Immunomodulatory polypeptides and related compositions and methods | |
| IL251774B (en) | Methods and compositions for dosing in adoptive cell therapy | |
| RU2017123548A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток, и их применение | |
| Schabowsky et al. | A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity | |
| White et al. | FcγRIIB as a key determinant of agonistic antibody efficacy | |
| Karmakar et al. | Key activating and inhibitory ligands involved in the mobilization of natural killer cells for cancer immunotherapies | |
| Ostrand-Rosenberg et al. | Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells | |
| Flies et al. | Comparative analysis of immune checkpoint molecules and their potential role in the transmissible Tasmanian devil facial tumor disease | |
| Huang et al. | The breakthroughs in cancer immune checkpoint based therapy: a review of development in immune checkpoint study and its application | |
| Nakajima et al. | Cancer immunotherapy targeting co-signal molecules | |
| WO2024240112A1 (zh) | 免疫效应细胞及其应用 | |
| Guerra | Patterns of T cell co-stimulation and co-inhibition in tumor microenvironment conditions, in vitro | |
| Duhen et al. | AGONISTIC ANTIBODIES IN CANCER IMMUNOTHERAPY |